| Abstrakt: |
Hoth Therapeutics has announced positive pre-clinical research results for their Alzheimer's disease therapeutic, HT-ALZ. The study showed that HT-ALZ, which targets the Substance P/Neurokinin 1 Receptor pathway, reduces soluble Ab levels in the brain's interstitial fluid, diminishes anxiety-like behavior, and enhances cognitive function in preclinical models. While the effects on plaque deposition and Ab levels were inconclusive, the treatment's cognitive benefits suggest that HT-ALZ may reduce brain inflammation and improve cognitive outcomes for Alzheimer's patients. Hoth Therapeutics plans to continue researching HT-ALZ's effects on microglial activation and brain inflammation. [Extracted from the article] |
